Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)00681-6
Affiliations:
20
Authors:
277
Go to article
Institutions Authors Share
Janssen Research & Development, LLC (J&J PRD), United States of America (USA)
6.000000
 0.27
Johnson & Johnson, United States of America (USA)
2.000000
 0.09
Otsuka America Pharmaceutical, Inc., United States of America (USA)
1.000000
 0.05
Medical University of Vienna (MUW), Austria
1.000000
 0.05
University of Cincinnati (UC), United States of America (USA)
1.000000
 0.05
Alimentiv, Canada
1.000000
 0.05
The University of Chicago Medicine, United States of America (USA)
1.000000
 0.05
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
1.000000
 0.05
IRCCS San Raffaele Hospital (HSR), Italy
1.000000
 0.05
Amsterdam UMC, Netherlands
1.000000
 0.05
University of Calgary (U of C), Canada
1.000000
 0.05
Johnson & Johnson, Belgium, Belgium
1.000000
 0.05
Johnson & Johnson, Switzerland, Switzerland
1.000000
 0.05
Kyorin University, Japan
1.000000
 0.05
Central Adelaide Local Health Network (CALHN), Australia
0.500000
 0.02
The University of Adelaide (Adelaide Uni), Australia
0.500000
 0.02
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain
0.500000
 0.02
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Spain
0.500000
 0.02
Interested in Clinical Sciences?